
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Nelnet, you need to be comfortable with a business that pairs uneven earnings with a steady commitment to shareholder returns. The latest quarter’s softer net income and EPS, alongside a maintained US$0.33 dividend, mostly reinforces that story rather than rewriting it. In the near term, the more meaningful catalysts still look like Q2 2026 earnings, any signalling around dividend sustainability, and how the new US$435 million unsecured credit line is used. The Q1 results do, however, slightly sharpen one existing risk: profit volatility in a company already trading at a higher earnings multiple than many Consumer Finance peers. With the share price down over the past month, the market does not appear to see this quarter as a thesis-breaker, but it does keep execution firmly in focus.
However, there is a capital allocation risk investors should not ignore. Nelnet's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.Explore 2 other fair value estimates on Nelnet - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com